

FAX MESSAGE

REGISTRATION AND B/T RANDOMISATION REQUEST STUDY ENTRY

DATE (dd/mm/yyyy):

<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------

ATTENTION:

UKALL14 TRIAL TEAM

UKALL14 FAX No:

0207 679 9861

Number of pages (including cover sheet):

<input type="text"/>	<input type="text"/>
----------------------	----------------------

RESEARCH CONTACT:

PHONE NO:

FAX NO:

PHARMACY CONTACT:

PHONE NO:

FAX NO:

Centre

Consultant

Patient Initials

Date of Birth

UKALL14 Registration at Study Entry (1/9)*Patient Details*

Patient Initials

NHS Number

Date of Birth (dd/mm/yyyy)

Sex (1=Male, 2=Female)

Date of ALL Diagnosis
(dd/mm/yyyy)

Disease Type:

1= Precursor-B cell Disease

2= T-cell disease

Centre

Consultant

Has steroid pre-phase started? (1=Yes, 2=No)

If yes, steroid pre-phase start date
(dd/mm/yyyy)Proposed start date of Induction Phase 1
(dd/mm/yyyy)**REMINDER****Pegylated-Asparaginase is an IMP****Protocol Section 7.2.3—Phase 1 Induction****All patients will receive Phase 1 Induction regardless of phenotype.****Please ensure sufficient drug supply is available to treat Philadelphia Negative patients.**

UKALL14 Registration at Study Entry (2/9)

Eligibility Checklist

ANSWERS TO THE FOLLOWING QUESTIONS MUST BE YES

	Inclusion Criteria for STUDY ENTRY	Yes	No
a	Aged ≥ 25 and ≤ 65 years at registration OR aged ≥ 19 and ≤ 65 years with Philadelphia Chromosome present.		
b	Newly diagnosed and previously untreated ALL - Acute Lymphoblastic Leukaemia. A steroid pre-phase of 5-7 days is required and can be started prior to registration.		
c	Written informed consent.		

ANSWERS TO THE FOLLOWING QUESTIONS MUST BE NO

	Exclusion Criteria for STUDY ENTRY	Yes	No
a	Known HIV infection.		
b	Hepatitis B infection (defined as positive HBsAg and/or HBcAb). Note: Antibodies to Hep B surface antigen only is acceptable.		
c	Hepatitis C infection (antibodies against hepatitis C or PCR evaluation which is positive for hepatitis C DNA).		
d	Pregnant or lactating woman.		
e	Blast transformation of CML.		
f	Mature B-cell leukaemia i.e. Burkitt's lymphoma t(8;14)(q24 ;q32) and variant c-myc translocations e.g. t(2;8)(p12 ;q24), t(8;22)(q24;q11).		

Viral Serology

Test Date (dd/mm/yyyy):	Positive	Negative
Hep B surface antigen (HBsAg)		
Hep C antibodies or Hep C DNA (HCV DNA)		
Hep B core antibody (HBcAb) *		

*Eligibility confirmed by treating clinician
(name): _____

Date (dd/mm/yyyy)

<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------

REMINDER

Protocol section 8.2.1—Schedule of testing for MRD and correlative science testing.

Please send baseline samples and begin tissue typing of patient and any siblings.

If there is not a matched sibling donor available, please initiate the search for a donor as soon as possible to avoid unnecessary delays.

UKALL14 Registration at Study Entry (3/9)**Pre-registration & Pre-1st Randomisation Evaluations****Patient Assessments**

Date of assessments (dd/mm/yyyy)

Height (cm)

Weight (kg)

ECOG Performance Status

Medical History – Cardiac*

Has the patient been diagnosed with a serious cardiac condition? (1=Yes, 2=No)

If yes, please specify below (1=Yes, 2=No)

Angina

Myocardial Infarction

Heart failure

Other (specify)

Medical History – Mental Health*

Any history of mental health issues pre ALL diagnosis? (1=Yes, 2=No)

If Yes, please complete below (1=Yes, 2=No):

Diagnosis of Depression

Attempted suicide/self harm

Psychotic illness

Anxiety

Other (specify)

On anti-depressants now? (1=Yes, 2=No)

This information is needed as a baseline for the late effects assessment at 2yrs post treatment*Employment status**

Employed now? (1=Yes, 2=No)

If yes, current
occupation**Pregnancy Test**

Is the patient a female of child bearing age? (1=Yes, 2=No)

If yes, NEGATIVE pregnancy test date (dd/mm/yyyy)

UKALL14 Registration at Study Entry (4/9)**Pre-registration & Pre-1st Randomisation Evaluation****CNS Involvement**

Lumbar Puncture is only required at baseline if CNS involvement suspected, otherwise should be avoided until the first dose of intrathecal methotrexate is due

Does the patient have suspected CNS involvement? (1=Yes 2=No)

If Yes above then please complete below:

Date of Lumbar Puncture (dd/mm/yyyy)

Number of white cells/ μ L

Number of red cells/ μ L

Extramedullary involvement

Date of Assessment (dd/mm/yyyy)

Does the patient have extramedullary involvement? (1=Yes 2=No)

If yes, please complete all boxes below (1= Involved, 2=Not Involved, 3=Not Applicable)

Liver Is the liver enlarged? (1= Yes 2=No)

Spleen Is the spleen enlarged? (1= Yes 2=No)

Mediastinum Anterior mediastinal mass on chest X-ray? (1= Yes 2=No)

Lymph nodes Any superficial lymph nodes enlarged? (1= Yes 2=No)

Testes

Other (specify)

Other (specify)

Other (specify)

UKALL14 Registration at Study Entry (5/9)

Haematology & Biochemistry

Test should be from date of diagnosis. If these are not available, results prior to the steroid pre-phase must be given.

Date of Haematology (dd/mm/yyyy)

White Blood Cell (WBC) Count x10⁹/L

Haemoglobin g/dL OR g/L (circle units)

Neutrophils x 10⁹/L

Platelets x 10⁹/L

Is the % Bone Marrow Blasts result available at this time? Yes No

Result

Reason:
1—Pending*
2—Unobtainable**

* Please send in an anonymised diagnosis report confirming ALL. Once the diagnosis sample result is available please update this page and fax to UCL-CTC.

** Please send in an anonymised diagnosis report confirming ALL.

Date of Biochemistry (dd/mm/yyyy)

Calcium (mmol/L)

Potassium (mmol/L)

Phosphate (mmol/L)

Urate (mmol/L)

Urea (mmol/L)

Creatinine (µmol/L)

Creatinine Clearance (ml/min)

Glucose (mmol/L)

UKALL14 Registration at Study Entry (6/9)

Liver Function Tests

Test should be from date of diagnosis. If these are not available, results prior to the steroid pre-phase must be given.

Date of Liver Function
Tests (dd/mm/yyyy)

Albumin (g/L)

Bilirubin ($\mu\text{mol/L}$)

Alkaline Phosphatase (IU/L)

Total Protein (g/L)

Aspartate Transaminase (IU/L)

Alanine Transaminase (IU/L)

Gamma-glutamyltransferase (U/L)

UKALL14 Registration at Study Entry (7/9)

Medical History

Does the patient have a significant medical history or baseline symptoms? (1=Yes, 2=No)

If yes, please complete the table below:

Enter details of all significant conditions, past or present, e.g. hypertension, allergies, including **past** malignancies. Do **not** include **current** malignancy.

If a condition is continuing, e.g. uncontrolled hypertension, please report the CTCAE (v4.0) Grade and enter C as the end date.

	Condition Use the CTCAE (v4.0) adverse event name if possible	Status 1=Resolved/ Asymptomatic 2= Continuing	Onset Date (dd/mm/yyyy)	End Date (dd/mm/yyyy)	Severity Grade (0-4)	Treatment Ongoing 1=Yes, 2=No
1						
2						
3						
4						
5						
6						

Family History of Cancer

Have any of the patient's first degree relatives (mother, father, sister, brother) had cancer?

(1=Yes, 2=No) If yes, please enter details below.

Relative	Type and Site of Cancer	Age at Diagnosis

UKALL14 Registration at Study Entry (8/9)

Informed Consent

This section should be completed only if all criteria on the Eligibility Checklist have been satisfied

Date Patient Information
Sheet given to patient
(dd/mm/yyyy)

Version number of Patient
Information Sheet

Date patient signed **Part 1** of
the Consent Form
(dd/mm/yyyy)

Version number of
Consent Form

Has the patient signed **Part 2**
of the Consent Form
(1=Yes, 2=No)

Date **Part 2** of the Consent
Form signed (dd/mm/yyyy)

N.B. Part 2 is not mandatory

On **Part 2** of the Consent Form, which boxes did the patient initial?

1=Only box 1, 2=Only box 2, 3=Both boxes, 4=N/A

The patient has initialled all the boxes on
the consent form (1=Yes, 2=No)

The patient has personally signed and
dated the consent form (1=Yes, 2=No)

The person taking consent has signed and dated
the form on the same date as the patient
(1=Yes, 2=No)

The person taking consent has been
delegated this role on the delegation log
(1=Yes, 2=No)

Name of person taking consent

UKALL14 Registration at Study Entry (9/9)

Informed Consent for Constitutional DNA

Buccal swab collection

Date Patient Information
Sheet given to patient
(dd/mm/yyyy)Version number of Patient
Information Sheet:Has the patient signed the Genetic
Testing Consent Form (1=Yes, 2=No)
N.B. Participation is optional

If yes, please provide details below.

Date patient signed Genetic
Testing Buccal Swab Consent
Form (dd/mm/yyyy)Version number Consent
FormThe patient has initialled all the boxes on
the consent form (1=Yes, 2=No)The patient has personally signed and
dated the consent form (1=Yes, 2=No)The person taking consent has signed and dated
the form on the same date as the patient
(1=Yes, 2=No)The person taking consent has been
delegated this role on the delegation log
(1=Yes, 2=No)

Name of person taking consent

Completed
by:

Signature:

Date
completed:

D	D	M	M	Y	Y	Y	Y
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Trial Information & Randomisation Result

(TO BE COMPLETED BY UCL CTC):

Trial Number

14

Precursor B – cell ALL

Key:**B1** = Standard Phase 1 Induction**B2** = Standard Phase 1 Induction + Rituximab

T-cell ALL

Key:**T1** = Standard Phase 1 & 2 Induction**T2** = Standard Phase 1 & 2 Induction followed by Nelarabine

Randomised by (UCL CTC)

Date of Randomisation
(dd/mm/yyyy)